Jonathan Jackson, PhD, DABT

Draft original scientific proposals, ensure effective collaboration with clients, and maintain strict adherence to quality standards within laboratory operations. This role prioritizes delivering timely, high-caliber service within advanced organ toxicity and ADME applications, using established or building innovative complex in vitro models (CIVM). Provide training to junior staff to enhance their proficiency in assay development, aligning all testing and study designs with relevant regulatory frameworks (OECD, GLP, ISO, IHC). Promote collaboration with both internal and external stakeholders to drive scientific excellence, strategic growth, and ongoing improvement.

Successfully managed preclinical screenings, developed innovative screening strategies, and led advancements in cell and microphysiological systems for organ toxicity and ADME applications. Expertly advised therapeutic area teams on potential safety issues, formulated strategies for comprehensive drug safety assessments, and interpreted toxicological data to inform portfolio decisions. Delivered high-quality toxicology data for portfolio progression and understanding nonclinical findings. Conducted scientific and business evaluations of technologies, assays, and advancements to make robust portfolio decisions. Proposed science and technology investments for Global Discovery and Investigative Toxicology. Reviewed internal and external data to support in vitro-in vivo or nonclinical-clinical translation. Communicated and collaborated effectively with local and global DSRD peers.

As a Senior Study Director at BioIVT, I managed, designed, and interpreted contracted in vitro drug and chemical safety assessment studies in accordance with regulatory guidelines (e.g. USFDA and EMA) to predict adverse effects including hepatotoxicity. Emphasis on drug transporter, drug metabolism, cell signaling, drug-drug interactions, and DILI mechanisms.

A staff scientist of Life Technologies (ADME/Tox R&D Business Unit; Durham, NC) has the responsibility to research and develop new products or processes to provide next generation drug development tools for the evaluation of drug disposition, drug metabolism, drug-drug interactions, and drug toxicity.

Managed, designed, and implemented contracted in vitro drug metabolism and drug-drug interaction studies including cytochrome P450 induction studies, cytochrome P450 inhibition studies, cytochrome P450 reaction phenotyping studies, intrinsic clearance studies, and plasma protein binding studies. Performed data analysis, interpreted results, and communicated study findings in a formal written report. Consulted with client to determine if follow-up studies were necessary.

Investigated the effects of nonalcoholic fatty liver disease (NAFLD) on drug metabolism and disposition by 1) studying the effects of NAFLD on the expression of drug metabolism enzymes and drug transporters, 2) examining the mechanisms of altered drug metabolism and drug transport as a result of NAFLD, and 3) determining the molecular mechanisms involved in the transcriptional regulation of drug metabolism enzymes and drug transporters in NAFLD.